A detailed history of Bank Of America Corp transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 508,233 shares of ZNTL stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
508,233
Previous 475,956 6.78%
Holding current value
$1.95 Million
Previous $7.5 Million 72.3%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $132,012 - $520,628
32,277 Added 6.78%
508,233 $2.08 Million
Q1 2024

May 15, 2024

SELL
$10.83 - $16.49 $2.63 Million - $4 Million
-242,687 Reduced 33.77%
475,956 $7.5 Million
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $4.46 Million - $9.12 Million
453,159 Added 170.69%
718,643 $10.9 Million
Q2 2023

Aug 14, 2023

SELL
$17.41 - $30.05 $605,972 - $1.05 Million
-34,806 Reduced 11.59%
265,484 $7.49 Million
Q1 2023

May 12, 2023

BUY
$16.14 - $24.94 $967,593 - $1.5 Million
59,950 Added 24.94%
300,290 $5.16 Million
Q4 2022

Feb 10, 2023

BUY
$18.07 - $25.6 $2.14 Million - $3.03 Million
118,205 Added 96.78%
240,340 $4.84 Million
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $3.79 Million - $5.94 Million
-187,332 Reduced 60.53%
122,135 $2.65 Million
Q2 2022

Aug 12, 2022

BUY
$17.91 - $52.25 $451,672 - $1.32 Million
25,219 Added 8.87%
309,467 $8.7 Million
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $3.61 Million - $7.03 Million
86,859 Added 44.0%
284,248 $13.1 Million
Q4 2021

Feb 08, 2022

BUY
$66.92 - $84.79 $7.56 Million - $9.58 Million
113,038 Added 134.01%
197,389 $16.6 Million
Q3 2021

Nov 15, 2021

BUY
$46.83 - $73.5 $118,198 - $185,514
2,524 Added 3.08%
84,351 $5.62 Million
Q2 2021

Sep 13, 2021

BUY
$37.41 - $62.25 $3.06 Million - $5.09 Million
81,827 New
81,827 $4.35 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $219M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.